The Top25 showed a markedly inferior prognosis (median survival = 7.8 yrs) compared to the Lower75 (undefined median survival; p=0.003, Log-Rank test), indicating that expression of the C/EBPβ signature inversely correlates with survival in HR-negative BC (Figures 3A, B). Here, CEBPB is linked to breast cancer.